About | Free Trial

Last Update

2016-01-28T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Mark Taylor?

Mr. Mark Taylor Thomas

Managing Director, Phamaceuticals

Roth Capital Partners , LLC

Direct Phone: (949) ***-**** ext. ****       

Roth Capital Partners , LLC

888 San Clemente Drive

Newport Beach, California 92660

United States

Company Description

ROTH Capital Partners, LLC (ROTH) is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, mark... more

Find other employees at this company (282)

Background Information

Employment History

Co-Founder and Chief Executive Officer
Hallux, Inc

Analyst
Oculus Innovative Sciences , Inc.

Affiliations

Board Member
Medical Care Corporation

Education

Bachelor of Science degree

Tulane University

D.M.D.

Web References (175 Total References)


Mark ...

halluxinc.com [cached]

Mark Taylor

...
Mark Taylor has over 20 years in the specialty pharmaceuticals sector serving as a senior executive of several public companies, and as a sell-side pharmaceutical analyst.
Most recently, Mr. Taylor was Senior Vice President of Corporate Development for Obagi Medical Products Inc., the market share leader in physician-dispensed dermatologics. Valeant Pharmaceuticals International acquired Obagi in April 2013.
Prior to Obagi, Mr. Taylor was Vice President, Diagnostics for MP Biomedicals, LLC, a privately held global provider of infectious disease screening and confirmatory tests.
Mr. Taylor also served Roth Capital Partners for five years where he held the titles of Managing Director of Healthcare Banking and Senior Pharmaceutical Analyst.
Prior to Roth, Mr. Taylor was head of the largest division at ICN Pharmaceuticals Inc. (now Valeant Pharmaceuticals International) as Executive Vice President, North America. Under Mr. Taylor's leadership, ICN expanded its dermatology division by adding prescription products, physician dispensed skin care brands, and light activated devices to its portfolio.
Mr. Taylor also served as Vice President of Business Development at Watson Pharmaceuticals (now Allergan plc.), another large dermatology products provider. During this time Watson made its first foray into dermatology products by acquiring Oclassen Pharmaceuticals, Inc.
Mark is a graduate of Tulane University and serves on the board of Medical Care Corporation, a private company focused on Alzheimer's research and diagnosis.


Mark ...

www.rothchina.com [cached]

Mark Taylor Institutional Sales Professional

mtaylor@roth.com
949-720-7133


ROTH Capital Partners | Institutional Sales Team | Investment Banking

roth.com [cached]

Mark Taylor Institutional Sales Professional

mtaylor@roth.com
949-720-7133


ROTH Capital Partners | Institutional Sales Team | Investment Banking

ww.w.rothcp.com [cached]

Mark Taylor Institutional Sales Professional

mtaylor@roth.com
949-720-7133


ROTH Capital Partners | Institutional Sales Team | Investment Banking

www.roth.com [cached]

Mark Taylor Institutional Sales Professional

mtaylor@roth.com
949-720-7133

Similar Profiles

Other People with this Name

Other people with the name Taylor

Shirley Taylor

Sam Taylor

Kim Taylor
Capacity Southeast Agency

Charlene Taylor
Community Resources for Justice Inc

Doug Taylor
Enfield Council

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory